{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:04:50Z","timestamp":1782907490116,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Long-term enzyme replacement therapy (ERT) may improve prognosis in the patients with Fabry disease (FD), however, detail psychosocial burden has not been focused on long life expectancy. We experienced a male case of FD under ERT, he was placed on hemodialysis and presented rapidly progressive cognitive function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 51-year-old male patient with FD has been receiving ERT from age of 38\u00a0years. Hemodialysis was initiated at the age of 47\u00a0years. The patient experienced several attacks of cerebral infarction, and brain images demonstrated wide-spread asymptomatic ischemic lesions. His behavior became problematic at the age of 51\u00a0years. He often exhibited restlessness during hemodialysis sessions and failure to communicate effectively. The patient experienced impairment of attention and executive function, topographical disorientation, and amnesia. Consequently, it was necessary for medical staff and family members to monitor his behavior for safe extracorporeal circulation and daily life activities. Annual standardized neuropsychiatric testing revealed worsening of cognitive performance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite treating with long-term ERT, it is necessary to determine the psychosocial burden derived from the progression of cognitive impairment in patients with FD undergoing hemodialysis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-024-03624-9","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T13:02:01Z","timestamp":1717419721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Isao","family":"Ohsawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Onuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Kanaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"11","key":"3624_CR1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"K MacDermot","year":"2001","unstructured":"MacDermot K, Holmes A, Miners A. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750\u201360.","journal-title":"J Med Genet"},{"issue":"5","key":"3624_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138.","journal-title":"J Med Genet"},{"issue":"2","key":"3624_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ymgme.2018.04.008","volume":"124","author":"K Hongo","year":"2018","unstructured":"Hongo K, Ito K, Date T, Anan I, Inoue Y, Morimoto S, Ogawa K, Kawai M, Kobayashi H, Kobayashi M. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients. Mol Genet Metab. 2018;124(2):143\u201351.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3624_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13760-020-01484-2","volume":"121","author":"G Loret","year":"2021","unstructured":"Loret G, Miatton M, Vingerhoets G, Poppe B, Hemelsoet D. A long-term neuropsychological evaluation in Fabry disease. Acta Neurol Belg. 2021;121(1):191\u20137.","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"3624_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","volume":"37","author":"FE Bolsover","year":"2014","unstructured":"Bolsover FE, Murphy E, Cipolotti L, Werring DJ, Lachmann RH. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014;37(2):177\u201387.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"3624_CR6","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/jimd.12271","volume":"43","author":"S K\u00f6rver","year":"2020","unstructured":"K\u00f6rver S, Geurtsen GJ, Hollak CE, van Schaik IN, Longo MG, Lima MR, Dijkgraaf MG, Langeveld M. Cognitive functioning and depressive symptoms in Fabry disease: a follow-up study. J Inherit Metab Dis. 2020;43(5):1070\u201381.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3624_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.14789\/jmj.60.353","volume":"60","author":"Y Makita","year":"2014","unstructured":"Makita Y, Tanaka Y, Shimizu Y, Takeda Y, Kanamaru Y, Ohsawa I, Suzuki Y, Kurusu A, Horikoshi S, Tomino Y. A case of Fabry disease, in which renal symptoms served as a diagnostic prompt. Juntendo Medical Journal. 2014;60(4):353\u20137.","journal-title":"Juntendo Medical Journal"},{"issue":"2","key":"3624_CR8","first-page":"20","volume":"4","author":"Y Imai","year":"1994","unstructured":"Imai Y, Hasegawa K. The revised Hasegawa\u2019s dementia scale (HDS-R)-evaluation of its usefulness as a screening test for dementia. East Asian Arch Psychiatry. 1994;4(2):20.","journal-title":"East Asian Arch Psychiatry"},{"issue":"3","key":"3624_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"key":"3624_CR10","volume-title":"COGNISTAT: The Neurobehavioral Cognitive Status Examination manual","author":"R Kiernan","year":"1995","unstructured":"Kiernan R, Mueller J, Langston J. COGNISTAT: The Neurobehavioral Cognitive Status Examination manual. Fairfax: Northern California Neurobehavioral Group; 1995."},{"issue":"3","key":"3624_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.neulet.2005.03.038","volume":"382","author":"Y Hirata","year":"2005","unstructured":"Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, Asada T, Iwabuchi S, Samejima H. Voxel-based morphometry to discriminate early Alzheimer\u2019s disease from controls. Neurosci Lett. 2005;382(3):269\u201374.","journal-title":"Neurosci Lett"},{"issue":"7","key":"3624_CR12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/arclin\/acu047","volume":"29","author":"L Sigmundsdottir","year":"2014","unstructured":"Sigmundsdottir L, Tchan MC, Knopman AA, Menzies GC, Batchelor J, Sillence DO. Cognitive and Psychological Functioning in Fabry Disease. Arch Clin Neuropsychol. 2014;29(7):642\u201350.","journal-title":"Arch Clin Neuropsychol"},{"issue":"2","key":"3624_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1468-1331.2010.03155.x","volume":"18","author":"I Schermuly","year":"2011","unstructured":"Schermuly I, Muller MJ, Muller KM, Albrecht J, Keller I, Yakushev I, Beck M, Fellgiebel A. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol. 2011;18(2):347\u201353.","journal-title":"Eur J Neurol"},{"issue":"5","key":"3624_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1440-1789.2008.00883.x","volume":"28","author":"R Okeda","year":"2008","unstructured":"Okeda R, Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology. 2008;28(5):532\u201340.","journal-title":"Neuropathology"},{"issue":"2","key":"3624_CR15","first-page":"121","volume":"47","author":"K Itoh","year":"2005","unstructured":"Itoh K, Tanaka M, Matsushita K, Miyamura N, Nishida K, Araki E, Nonoguchi H, Tomita K. Clinical courses of two male siblings on hemodialysis for Fabry disease. Nihon Jinzo Gakkai Shi. 2005;47(2):121.","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"1","key":"3624_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-37320-0","volume":"9","author":"S K\u00f6rver","year":"2019","unstructured":"K\u00f6rver S, Geurtsen GJ, Hollak CE, van Schaik IN, Longo MG, Lima MR, Vedolin L, Dijkgraaf MG, Langeveld M. Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease. Sci Rep. 2019;9(1):1\u201312.","journal-title":"Sci Rep"},{"issue":"6","key":"3624_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1159\/000369293","volume":"38","author":"A Fellgiebel","year":"2014","unstructured":"Fellgiebel A, Gartenschl\u00e4ger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis. 2014;38(6):448\u201356.","journal-title":"Cerebrovasc Dis"},{"issue":"21","key":"3624_CR18","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.3390\/ijms21218080","volume":"21","author":"I Simonetta","year":"2020","unstructured":"Simonetta I, Tuttolomondo A, Daidone M, Pinto A. Biomarkers in Anderson-Fabry Disease. Int J Mol Sci. 2020;21(21):8080.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3624_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst G, Zwinderman A, Wijburg F, Kuiper S, Groener J, Poorthuis B, Hollak C. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophy Acta. 2010;1802(9):741\u20138.","journal-title":"Biochim Biophy Acta."},{"key":"3624_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22:843\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"3624_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.nefroe.2022.03.008","volume":"43","author":"EC Prats","year":"2023","unstructured":"Prats EC, Gonz\u00e1lez-Parra E, Vega A, Mac\u00edas N, Delgado M, Fern\u00e1ndez M, S\u00e1nchez RJ, \u00c1lvarez L, Miranda RJ, Vian J. Epidemiology of Fabry disease in patients in hemodialysis in the Madrid community. Nefrolog\u00eda (English Edition). 2023;43(4):435\u201341.","journal-title":"Nefrolog\u00eda (English Edition)"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03624-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T13:04:48Z","timestamp":1717419888000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03624-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3624"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03624-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}